Douglas Yao
An alternative, more direct strategy that avoids the side effects of Cobenfry altogether is to design the muscarinic agonist to be ‘subtype-specific’ - that is, activate only M4, and not any of the other muscarinic receptors. This is exactly what PAC-3310 does. (3/7)